Aim immunotech reports positive topline results from phase 2 study evaluating ampligen® for the treatment of post-covid conditions

Efficacy results offer preliminary evidence that ampligen may reduce fatigue in subjects with post-covid conditions
AIM Ratings Summary
AIM Quant Ranking